Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melan-A VLP vaccine + IMP321
- Development stage
- Unknown
- Lead developer
- Immutep
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Melan-A VLP vaccine + IMP321 is an investigational combination immunotherapy designed for the treatment of melanoma. The Melan-A VLP vaccine consists of the melanocyte differentiation antigen Melan A (also known as MART-1) encapsulated in noninfectious virus-like particles (VLPs), which are engineered to stimulate a robust immune response against melanoma cells expressing this antigen[1][3]. IMP321, also known as LAG-3Ig or eftilagimod alpha, is an immune adjuvant that acts as an agonist of MHC class II molecules on antigen-presenting cells, enhancing T cell activation and amplifying anti-tumor immunity. The combination aims to induce strong tumor-specific CD8+ T cell responses by presenting the Melan-A antigen in a highly immunogenic format and boosting dendritic cell function via IMP321. This approach leverages both direct vaccination against a tumor-associated antigen and broad immune system activation to improve clinical outcomes in patients with melanoma[3].
- Other names
- Melan-A VLP vaccine + IMP321CYT004-MelQbG10 + IMP321Melan-A/MART-1 VLP vaccine + eftilagimod alpha
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on Melan-A VLP vaccine + IMP321.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melan-A VLP vaccine + IMP321.